Close Menu

Biodesix

On a conference call last month following the release of its Q1 earnings, Vermillion CEO Thomas McLain announced that the company would be taking over from Quest Diagnostics as leader of commercialization efforts for its OVA1 ovarian cancer diagnostic (

NEW YORK (GenomeWeb News) – Biodesix has secured Medicare coverage for its VeriStrat lung cancer test, the company announced today.

Biodesix this week reported results from the first prospective clinical trial of its proteomic lung cancer test Veristrat.

In March 2010, Austin, Texas-based diagnostics firm Vermillion launched sales of its OVA1 ovarian cancer test.

Bruker and the University of Victoria-Genome British Columbia Proteomics Centre said this week that they are collaborating on high-throughput iMALDI mass spec-based assays for determining genetic hemoglobin variants and diabetes risk.

Biodesix said this week it has entered a collaborative agreement with Bruker to support its VeriStrat diagnostic test, as well as future tests based on MALDI-TOF mass spectrometry.

NEW YORK (GenomeWeb News) – Biodesix said it has entered a collaborative agreement with Bruker Daltonics to support its VeriStrat diagnostic test as well as future tests based on MALDI-TOF mass spectrometry.

Researchers affiliated with Biodesix have completed a study indicating that the company's Veristrat test for identifying non-small cell lung cancer patients likely to respond to tyrosine kinase inhibitor treatment plays a significant role in guiding physician decisions.

Biodesix said this week that data from an analysis of serum and plasma samples from a Phase II non-small cell lung cancer study demonstrate that its Veristrat test is able to identify patients likely to benefit when treated with erlotinib – marketed by Roche as Tarceva – and erlo

NEW YORK (GenomeWeb News) – Biodesix today announced the closing of a $12 million extension of its Series D financing round.

Pages

According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.

NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.

A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.

In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.